Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27018597 | 0.83 | SPHK1 (0.46) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL17020050 | 0.83 | SPHK1 (0.46) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL27018593 | 0.80 | SPHK1 (0.43) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL27018595 | 0.79 | SPHK1 (0.45) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL1835688 | 0.75 | SPHK1 (0.46) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL3464690 | 0.74 | SPHK1 (0.42) | SPHK1BRD4HSD11B2 | |
| SCHEMBL3464686 | 0.74 | SPHK1 (0.42) | SPHK1BRD4HSD11B2 | |
| SCHEMBL31228486 | 0.71 | SPHK1 (0.40) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL222671 | 0.71 | SPHK1 (0.50) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL222670 | 0.71 | SPHK1 (0.50) | SPHK1BRD4CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | SPHK1 2072/4885BRD4 2440/4885CHRM2 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.